$SVA News

Sinovac Biotech H1 EPS $(0.84) Down From $0.06 YoY, Sales $147.079M Up From $130.270M YoY

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements

Sinovac Biotech Regains Compliance With Nasdaq Listing Requirements

SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report

Sinovac Biotech Requests Hearing Following New Delisting Determination Related To 2025 Annual Report Filing

Sinovac Biotech Has Extended The Deadline For Shareholders And Nominee Brokers To Submit Payment Instructions Relating Its Previously Declared Special Cash Dividend

Sinovac Biotech H1 Adj. EPS $0.06 Down From $1.18 YoY, Sales $130.270M Up From $128.711M YoY

Coxsackievirus Infections Market Research Report 2025-2035: High Burden of Pediatric and Neonatal Infections, Link to Type 1 Diabetes Risk, Advances in Vaccine Development Driving Expansion

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

Sinovac Biotech Says Nasdaq Hearings Panel Grants Continued Listing, Sets May 11, 2026 Deadline To File 2024 Form 20-F And Q2 2025 Form 6-K To Regain Compliance

Sinovac Biotech Says Nasdaq Hearings Panel Grants Continued Listing, Sets May 11, 2026 Deadline To File 2024 Form 20-F And Q2 2025 Form 6-K To Regain Compliance

Reported Sunday, Sinovac Discloses Nasdaq Notice Related To Delayed Filing Of 2025 Interim Financial Statements

SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting

Sinovac Biotech Announces Antigua High Court Makes Interim Order Giving Board Control Of The Company Until Trial Of Disputed 2025 Shareholder Meeting

SINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

Sinovac Biotech Receives Delisting Notice From Nasdaq; Co. Intends To Appeal Staff Determination